{"id":"oral-chenodeoxycholic-acid-stimulation","safety":{"commonSideEffects":[{"rate":null,"effect":"Pruritus"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Abdominal discomfort"},{"rate":null,"effect":"Steatorrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Chenodeoxycholic acid (CDCA) is an endogenous secondary bile acid that acts as a ligand for nuclear farnesoid X receptor (FXR) and G-protein coupled receptor TGR5. Upon oral administration, it enhances bile acid-dependent signaling to suppress hepatic bile acid synthesis, increase bile acid excretion, and improve cholestatic liver disease. This mechanism reduces the accumulation of toxic bile acids in the liver and improves hepatic and intestinal function.","oneSentence":"Chenodeoxycholic acid is a bile acid that activates farnesoid X receptor (FXR) and TGR5 signaling pathways to regulate bile acid metabolism and reduce cholestasis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:58:41.781Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Progressive familial intrahepatic cholestasis (PFIC)"},{"name":"Bile acid synthesis disorders"},{"name":"Cholestatic liver disease"}]},"trialDetails":[{"nctId":"NCT03059537","phase":"PHASE4","title":"Validation of Stimulated ∆FGF19 for Diagnosing Bile Acid Diarrhoea","status":"COMPLETED","sponsor":"Lars Kristian Munck","startDate":"2017-03-13","conditions":"Bile Acid Malabsorption","enrollment":71}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Chenodeoxycolic acid"],"phase":"marketed","status":"active","brandName":"Oral chenodeoxycholic acid stimulation","genericName":"Oral chenodeoxycholic acid stimulation","companyName":"Lars Kristian Munck","companyId":"lars-kristian-munck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Chenodeoxycholic acid is a bile acid that activates farnesoid X receptor (FXR) and TGR5 signaling pathways to regulate bile acid metabolism and reduce cholestasis. Used for Progressive familial intrahepatic cholestasis (PFIC), Bile acid synthesis disorders, Cholestatic liver disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}